Basilea Pharmaceutica (BSLN.SW) Reports Presentation of New Data on Anti-Infective Drug Candidates Addressing Drug Resistance
4/29/2013 12:24:12 PM
More...
|
Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica (BSLN.SW)
4/9/2013 12:15:07 PM
More...
|
Basilea Pharmaceutica (BSLN.SW)'s Board Proposes Martin Nicklasson to Succeed Chairman Werner Henrich and Recommends to Shareholders That They do Not Support the Request for a Capital Distribution at This Time
3/7/2013 9:49:43 AM
More...
|
Basilea Pharmaceutica (BSLN.SW) Receives Request to Place Repayment of CHF 48 Million From Capital Contribution Reserve on the Agenda of the Ordinary General Meeting of Shareholders
2/26/2013 9:14:42 AM
More...
|
Basilea Pharmaceutica (BSLN.SW) Reports Recruitment Completion of Phase 3 Pivotal Study of Isavuconazole, an Agent for the Potential Primary Treatment of Invasive and Life-Threatening Fungal Infections
12/14/2012 9:56:26 AM
More...
|
Basilea Pharmaceutica (BSLN.SW) Promotes Ronald Scott to CEO, Replacing Anthony Man
12/10/2012 7:40:15 AM
More...
|
Basilea Pharmaceutica (BSLN.SW) Initiates Next Phase 1 Multiple Ascending Dose Study With Antibiotic Bal30072 Active Against Multidrug-Resistant Gram-Negative Bacteria
11/26/2012 11:55:46 AM
More...
|
Basilea Pharmaceutica (BSLN.SW)'s Novel Oncology Drug Candidate BAL101553: Data Presented at International Conference Demonstrate Dual Mode of Action
11/6/2012 7:16:12 AM
More...
|
Basilea Pharmaceutica (BSLN.SW)'s European Marketing Authorization Application for ceftobiprole for the Treatment of Pneumonia Accepted for Review
10/5/2012 9:35:18 AM
More...
|
Basilea Pharmaceutica (BSLN.SW) Reports Presentation of New Data on Investigational Anti-Infectives Isavuconazole, Ceftobiprole and BAL30072 at ICAAC
9/12/2012 10:04:25 AM
More...
|
|